Takeda’s Post

Alpha-1 antitrypsin deficiency (AATD) can cause silent damage in the liver and have a significant impact on patients when diagnosis is delayed or mistaken for another chronic liver disease. We’re committed to advancing research to address the unmet needs of the AATD-associated #LiverDisease community. This year at The Liver Meeting, we’re presenting data that can build understanding of liver transcriptomic signatures, liver disease progression, non-invasive tests and AI-driven digital pathology approaches in clinical development. #TLM25 Intended only for health care professionals.